-
Jichuan Pharmaceutical Pudilan Anti-inflammatory Oral Liquid will be withdrawn from Shandong Medical Insurance List
Time of Update: 2021-09-05
’s main product Pudilan Xiaoyan Oral Liquid will be withdrawn from the “Shandong Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs” on November 1, 2021.
-
North China Pharmaceutical: nominate candidates for directorship and hire multiple senior executives
Time of Update: 2021-09-05
Liu Xinyan as a candidate for the company’s tenth board of directors and agreed to submit it to the company’s general meeting of shareholders for deliberation .
Liu Xinyan was appointed as the general manager of the company; Mr.
-
U.S. FDA grants Vivet/Pfizer VTX-801 fast track qualification
Time of Update: 2021-09-05
VTX-801 is a new type of research gene therapy, which will be evaluated in the Phase 1/2 GATEWAY trial (NCT04537377) to determine the safety, tolerability and pharmacological activity of a single intravenous infusion in the treatment of adults with Wilson disease .
-
The local Biotech wave is vigorous and the multinational MNC wolves are waiting for the traditional pharmaceutical companies. How to break the situation?
Time of Update: 2021-09-05
In this "involvement" in a race against time, traditional pharmaceutical companies must not only withstand the threats from domestic biotech and multinational giants, but also realize the transformation and upgrading from imitation to innovation while doing generic drugs .
-
The Medical Insurance Bureau issues a document that concerns all Chinese medicine companies
Time of Update: 2021-09-05
02 Times drive transformation02 Times drive transformationAt the 6th Changbai Mountain International Pharmaceutical and Health Industry Development Forum held in Tonghua·China Medical City, Zhu Xun, former expert of the National New Drug Advisory Committee, said on the current status of the pharmaceutical industry: The problem of transformation is not just traditional pharmaceutical companies, but companies that have already gone public are also facing severe challenges .
-
Announcement of the list of top 100 pharmacies and drug approvals in the country
Time of Update: 2021-09-05
7% of the total national pharmaceutical market during the same period, a year-on-year increase of 0.
From 2016 to 2020, the top 100 pharmaceutical retail companies accounted for an increasing market share.
-
Sagimet, a partner of Songli, completes the first phase IIb clinical administration of patients with moderate to severe fibrosis NASH
Time of Update: 2021-09-05
On August 16, Gerry Pharmaceuticals announced that its partner Sagimet Biosciences has completed the first patient administration of its non-alcoholic steatohepatitis (NASH) phase IIb clinical trial (FASCINATE-2) .
FASCINATE-2 is a randomized, double-blind, placebo-controlled phase IIb clinical trial that enrolled approximately 330 NASH patients with moderate to severe fibrosis (F2-F3) .
-
Pfizer's tick-borne encephalitis vaccine TICOVAC receives FDA approval
Time of Update: 2021-09-05
This approval also makes the TICOVAC vaccine the only tick-borne encephalitis vaccine supported by the FDA in the United States, which can protect people of almost all ages from the virus when visiting or living in areas where tick-borne encephalitis is endemic .
-
Hit the East Sunshine!
Time of Update: 2021-09-05
Currently, according to the Insight database, Dongyang Sunshine has two dosage forms of oseltamivir capsules and granules, and has also submitted an application for the marketing of oseltamivir dry suspension, which is currently under review and approval; at the same time, it has also applied for sustained-release tablets.
-
Innovative drug HSK21542 injection, a wholly-owned subsidiary of Haisco obtains clinical approval
Time of Update: 2021-09-05
According to the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the HSK21542 injection accepted on May 12, 2021 meets the relevant requirements of drug registration, and it is agreed to carry out the phase II clinical trial of "liver disease itching" .
-
Covid-19 vaccine from different manufacturers mixed, the third injection and the sequential immunization booster
Time of Update: 2021-09-05
Before the completion of the immunization program, the cross-manufacturer mix, the third injection, and whether the sequential immunization of vaccines with different technical routes can be carried out and whether they can cope with variant strains are the focus of recent industry attention .
-
Pfizer and Ferring have reached a collaboration on degarelix acetate for prostate cancer drug injection
Time of Update: 2021-09-05
On August 17, Pfizer and Ferring formally announced that the two parties have reached a cooperation agreement on Ferring’s authorization of Pfizer to exclusively be responsible for the commercial operation of degarelix acetate (brand name: Feimenger®), an innovative drug for the treatment of prostate cancer, in mainland China.
-
Hengrui Medicine's 3 new drugs approved for clinical treatment of diabetes and tumors
Time of Update: 2021-09-05
According to the latest announcement by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Hengrui Medicine's three new biological drugs have recently obtained
-
Eli Lilly's breast cancer drug Verzenios is recommended by NICE
Time of Update: 2021-09-05
CompilationTom LeeA few days ago, the draft NICE guidelines have recommended Eli Lilly's oral Verzenios (abemaciclib) twice a day for the treatment of hormone receptor-positive, HER2-negative breast cancer in adult patients with breast cancer that has spread to other parts of the body .
-
Zejing Pharmaceutical: Disclosure of research and development progress of Donafinil tosylate tablets
Time of Update: 2021-09-05
On the 16th, Zejing Pharmaceutical issued an announcement stating that Donafinil Tosylate Tablets is a multi-center, randomized, double-blind, placebo-controlled treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer (RAIR-DTC) The Phase III clinical trial (code name: ZGDD3) carried out a preset interim analysis, and the Independent Data Monitoring Committee (IDMC) reviewed the results and determined that the effectiveness and safety results were in line with expectations .
-
Jisi Yingda ERK kinase inhibitor was approved for clinical use
Time of Update: 2021-09-05
On August 16, JSI Indah announced that it had received the "Clinical Trial Notice" approved and issued by the National Medical Products Administration, and its extracellular regulated kinase (ERK) inhibitor JSI-1187 capsule was approved for treatment A clinical trial of patients with advanced solid tumors with mutations in the MAPK signaling pathway .
-
Anke Bio-Human Growth Hormone Injection has two new specifications
Time of Update: 2021-09-05
The therapeutic biological product "Human Growth Hormone Injection" independently developed by Anke Biological was approved by the National Food and Drug Administration in June 2019 (Specifications: 4IU/1.
-
Yang Xinqiu, deputy general manager of Ruizhi Pharmaceutical, resigns
Time of Update: 2021-09-05
On August 10, Ruizhi Pharmaceutical issued an announcement stating that the company had recently received a written resignation application report submitted by Deputy General Manager Yang Xinqiu.
-
Hebei Provincial Drug Administration: Remove restrictions on distance and business area for pharmaceutical retail companies
Time of Update: 2021-09-05
According to the "Notice on Optimizing the Approval for the Establishment of Pharmacies" (hereinafter referred to as the "Notice") issued by the Hebei Provincial Drug Administration recently, it is necessary to continue to optimize the approval services for the establishment of pharmacies, and to abolish the requirements for the set distance and business area of pharmaceutical retail companies.
-
Ocular terminates cooperation with Regeneron to develop aflibercept sustained-release formulations
Time of Update: 2021-09-05
Compiler: Fan DongdongA few days ago, Ocular Therapeutix and Regeneron announced the termination of their cooperation and the suspension of the development of aflibercept sustained-release preparations for the treatment of wet age-related macular degeneration (AMD) and other serious retinal diseases.
